L'accesso alle terapie oncologiche: Il costo è un problema che ci riguarda

Translated title of the contribution: Access to cancer care: The cost of treatment matters

Umberto Tirelli

Research output: Contribution to journalArticle


The approval of new antiviral agents and the wide-ranging costs of ophthalmic therapies with comparable efficacy have renewed the debate over the cost-effectiveness of novel drugs. In oncology, more expensive treatments do not always substantially change the outcome of the disease, but they merely prolong life expectancy by a few weeks even at the cost of significant side effects. Treatment costs are a key factor the physician should consider when sharing care decisions with the patient. In addition, fund allocation for purchasing high cost medications results in limited investment in clinical research and human resources - doctors, nurses and other healthcare staff - that play a central role in patient care. Regulatory agencies should be more demanding, reimbursing pharmaceutical companies on the basis of treatment outcome. Copyright - Il Pensiero Scientifico Editore.

Translated title of the contributionAccess to cancer care: The cost of treatment matters
Original languageItalian
Pages (from-to)181-183
Number of pages3
JournalRecenti Progressi in Medicina
Issue number5
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Access to cancer care: The cost of treatment matters'. Together they form a unique fingerprint.

  • Cite this